Market Growth –
The global in-vitro toxicology testing market
size is projected to reach USD 12.7 billion by 2024 from USD 8.1
billion in 2019, growing at a CAGR of 9.3%. The opposition to animal
testing, technological advancements, and increasing R&D expenditure
to detect toxicity at an early stage during drug development are the
primary growth factors for this market. Also, the increasing focus of
the pharmaceutical and cosmetics industries on using in-vitro methods
for product testing along with the improvement in silico methods for
predictive toxicology studies are expected to offer significant
opportunities for market growth in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065
Top Players –
Thermo
Fisher Scientific Inc. (US), Covance (US), Bio-Rad Laboratories, Inc.
(US), GE Healthcare (US), Eurofins Scientific SE (Luxembourg), Merck
KGaA (Germany), Charles River Laboratories International, Inc. (US),
Catalent, Inc. (US), Cyprotex (UK), SGS S.A. (Switzerland), QIAGEN N.V.
(Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT
(US), and MB Research Laboratories (US) are some key players in this
market. These companies are focusing on increasing their presence in
high-growth markets through both organic as well as inorganic growth
strategies such as product launches, acquisitions, and expansions.
Growth Strategies –
Thermo
Fisher Scientific was one of the leading players in the in-vitro
toxicology testing market in 2018. The company is a global manufacturer
of analytical instruments, laboratory equipment, software, consumables,
reagents, and services for the in-vitro toxicology testing market. Owing
to its strong sales and distribution network, the company has a
significant global footprint. The company leverages the advantage of
three well-established brands—Thermo Scientific, Fisher Scientific, and
Unity Lab Services. In February 2014, Thermo Fisher acquired Life
Technologies (US), thereby adding another brand name to its business.
Under the four brands mentioned above, the company has a robust product
portfolio for instruments, reagents, and services for life science
research.
Merck is a leading science and technology company with a
strong global presence in more than 120 countries. The company has a
portfolio of more than 300,000 life science products that support a
broad customer base. Merck majorly focuses on expansions in key
geographies to increase its customer base. The firm focuses explicitly
on the high-growth Asia Pacific region to increase its market share and
revenue. In the last three years, the firm opened life science centers
in China, India, South Korea, and Singapore to facilitate the supply of
its products in the region. Targeted acquisitions to complement or boost
its strengths form another key strategy for the company.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065
Eurofins
Scientific is a key competitor in the in-vitro toxicology testing
market, offering a unique range of analytical testing products and
services. The company has an elaborate service portfolio and a strong
product profile in ADME testing. It offers over 100 assays for profiling
drug toxicity in the in-vitro toxicology testing market. Eurofins aims
to provide quality services with high levels of safety in all operating
markets. The company is strengthening its competitive advantage through
consistent acquisitions in different regions.
